ArticleBiopharmaceutics & drug disposition2026
Pharmacokinetic Assessment of Atazanavir and Favipiravir Following Echinacea Supplementation: A Controlled Herb-Drug Interaction Investigation.
Article in Biopharmaceutics & drug disposition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echinacea is a widely used herbal supplement and is frequently co-administered with antiviral drugs, raising concerns regarding potential herb-drug interactions. This study evaluated the effect of repeated Echinacea administration on the pharmacokinetics of favipiravir and atazanavir in rats. Male Sprague Dawley rats were administered Echinacea (250 mg/kg) or vehicle once daily for 10 days, followed by a single oral dose of favipiravir (70 mg/kg) or atazanavir (35 mg/kg). Plasma drug concentrations were quantified using validated LC-MS/MS methods, and pharmacokinetic parameters were determined by noncompartmental analysis. Echinacea co-administration did not significantly alter favipiravir exposure (C
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.